Effect of the Marine Polyketide Plocabulin on Tumor Progression
Open Access
- 31 December 2022
- journal article
- review article
- Published by MDPI AG in Marine Drugs
- Vol. 21 (1) , 38
Abstract
Marine sponges represent one of the richest sources of natural marine compounds with anticancer potential. Plocabulin (PM060184), a polyketide originally isolated from the sponge Lithoplocamia lithistoides, elicits its main anticancer properties binding tubulin, which still represents one of the most important targets for anticancer drugs. Plocabulin showed potent antitumor activity, in both in vitro and in vivo models of different types of cancers, mediated not only by its antitubulin activity, but also by its ability to block endothelial cell migration and invasion. The objective of this review is to offer a description of plocabulin’s mechanisms of action, with special emphasis on the antiangiogenic signals and the latest progress on its development as an anticancer agent.Keywords
This publication has 49 references indexed in Scilit:
- Targeting Microtubules by Natural Agents for Cancer TherapyMolecular Cancer Therapeutics, 2014
- New Interfacial Microtubule Inhibitors of Marine Origin, PM050489/PM060184, with Potent Antitumor Activity and a Distinct MechanismACS Chemical Biology, 2013
- Isolation and First Total Synthesis of PM050489 and PM060184, Two New Marine Anticancer CompoundsJournal of the American Chemical Society, 2013
- Vascular Permeability and Drug Delivery in CancersFrontiers in Oncology, 2013
- Hallmarks of Cancer: The Next GenerationCell, 2011
- Genomic profiling reveals subsets of dedifferentiated liposarcoma to follow separate molecular pathwaysVirchows Archiv, 2009
- Antivascular Actions of Microtubule-Binding DrugsClinical Cancer Research, 2009
- Tubulin-Interactive Natural Products as Anticancer AgentsJournal of Natural Products, 2009
- Metronomic Chemotherapy Enhances the Efficacy of Antivascular Therapy in Ovarian CancerCancer Research, 2007
- The primary antimitotic mechanism of action of the synthetic halichondrin E7389 is suppression of microtubule growthMolecular Cancer Therapeutics, 2005